Shaanxi Bolin Biotechnology Co.,Ltd
Curcumin is a DYRK2 inhibitor. This new molecular target has good anticancer potential, is not only chemically sensitive, but also has anti-tumor inhibition and cancer-adapting potential.
Curcumin combined with FDA-approved multiple myeloma drug carfilzomib will greatly increase the chance of cancer cell death
Copyright © Shaanxi Bolin Biotechnology Co.,Ltd All Rights Reserved.